| Symbol | BBNX |
|---|---|
| Name | BETA BIONICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical/Dental Instruments |
| Address | 11 HUGHES,IRVINE, IRVINE, California, 92618, United States |
| Telephone | 949-427-7785 |
| Fax | — |
| — | |
| Website | https://www.betabionics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001674632 |
| Description | Beta Bionic is a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Our product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. Additional info from NASDAQ: |
Deadline Approaching: Beta Bionics, Inc. (BBNX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Read moreLevi & Korsinsky Reminds Beta Bionics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - BBNX
Read moreDeadline Soon: Beta Bionics, Inc. (BBNX) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Read moreBronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Read moreBBNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact SueWallSt
Read more📋 MARK HOPMAN (Officer) plans to sell 40K shares of BETA BIONICS, INC. (at $19.33 each, total $779K) Filed: Sep 09, 2026 | ID: 009247
Read moreBBNX Class Action Notice: Beta Bionics Sued for Securities Fraud After Allegedly Misleading Investors about the Safety of its Medical Device – Investors Urged to Contact BFA Law
Read moreLaw Offices of Frank R. Cruz Encourages Beta Bionics, Inc. (BBNX) Shareholders To Inquire About Securities Fraud Class Action
Read moreGlancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Beta Bionics, Inc. (BBNX) Shareholders To Inquire About Securities Fraud Class Action
Read moreBBNX Shareholder Alert: November 3, 2026 Lead Plaintiff Deadline in Beta Bionics, Inc. Securities Class Action - Contact Levi & Korsinsky
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07011147 | Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery | Na | Type 1 Diabetes (T1D) | Recruiting | 2026-01-16 | 2029-04-01 | ClinicalTrials.gov |
| NCT06449677 | Bionic Pancreas in CFRD | Phase3 | Cystic Fibrosis-related Diabetes | Recruiting | 2024-09-24 | 2027-03-30 | ClinicalTrials.gov |
| NCT06891898 | The iLet Experience Study | — | Type 1 Diabetes | Recruiting | 2024-05-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT04227626 | Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT | Na | Type 1 Diabetes | Withdrawn | 2021-04-01 | 2021-04-01 | ClinicalTrials.gov |
| NCT04200313 | The Insulin-Only Bionic Pancreas Pivotal Trial | Na | Diabetes Mellitus | Completed | 2020-03-31 | 2022-01-14 | ClinicalTrials.gov |
| NCT03840278 | The Bihormonal iLet Bionic Pancreas Feasibility Study | Phase2 | Type 1 Diabetes Mellitus | Completed | 2019-05-15 | 2019-07-03 | ClinicalTrials.gov |
| NCT02971228 | Feasibility Trial Testing the Bionic Pancreas With ZP4207 | Phase2 | Diabetes Mellitus, Type 1 | Completed | 2016-11-01 | 2017-06-07 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| iLet Dosing Decision Software | Other | Preclinical | Type 1 Diabetes | RECRUITING | NCT06891898 |
| Usual Care (UC) | Other | Phase PHASE3 | Cystic Fibrosis-related Diabetes | RECRUITING | NCT06449677 |
| iLet Bionic Pancreas System (BP) | Other | Phase PHASE3 | Cystic Fibrosis-related Diabetes | RECRUITING | NCT06449677 |
| Routine Care | Other | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| Bionic Pancreas | Other | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| GlucoSTAT | Other | Approved | Type 1 Diabetes | WITHDRAWN | NCT04227626 |
| Dasiglucagon | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| Insulin-only Bionic Pancreas | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| Bihormonal iLet Bionic Pancreas | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| iLet-based bionic pancreas | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| iPhone-based bionic pancreas | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| Glucagon | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| ZP4207 (dasiglucagon) | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| Insulin Lispro | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| BP Guidance Insulin Dosing | Other | Approved | Diabetes Mellitus | COMPLETED | NCT04200313 |
| Usual Care (UC) | Other | Approved | Diabetes Mellitus | COMPLETED | NCT04200313 |
| Bionic Pancreas with Fiasp (BPFiasp) | Other | Approved | Diabetes Mellitus | COMPLETED | NCT04200313 |
| Bionic Pancreas (BP) with Aspart or Lispro | Other | Approved | Diabetes Mellitus | COMPLETED | NCT04200313 |
| Usual Care (UC) | Other | Phase PHASE3 | Cystic Fibrosis-related Diabetes | RECRUITING | NCT06449677 |
| iLet Bionic Pancreas System (BP) | Other | Phase PHASE3 | Cystic Fibrosis-related Diabetes | RECRUITING | NCT06449677 |
| Routine Care | Other | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| Bionic Pancreas | Other | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| Routine Care | OTHER | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| Bionic Pancreas | DEVICE | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| Dasiglucagon | DRUG | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| Insulin-only Bionic Pancreas | DEVICE | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| Bihormonal iLet Bionic Pancreas | DEVICE | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| iLet-based bionic pancreas | DEVICE | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| iPhone-based bionic pancreas | DEVICE | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| Glucagon | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| ZP4207 (dasiglucagon) | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| Insulin Lispro | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |